Longitudinal peripheral blood lymphocyte subsets correlate with decreased disease activity in juvenile dermatomyositis

Journal of Rheumatology

Volumn 40, Issue 7, 2013, Pages 1200-1211

  Ernste, Floranne C ^a   Crowson, Cynthia S ^a   De Padilla, Consuelo Lopez ^a   Hein, Molly S ^a   Reed, Ann M ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

Dendritic Cells; Juvenile Dermatomyositis; Natural Killer Cells; Peripheral Blood Lymphocyte Cell Subtypes; T Cells

Indexed keywords

CD123 ANTIGEN; CD16 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; CD86 ANTIGEN; CREATINE KINASE; CYCLOSPORIN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD MYOSITIS ASSESSMENT SCALE; CLINICAL ARTICLE; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; JUVENILE DERMATOMYOSITIS; LYMPHOCYTE SUBPOPULATION; MALE; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PLASMACYTOID DENDRITIC CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; T LYMPHOCYTE; VISUAL ANALOG SCALE;

DENDRITIC CELLS; JUVENILE DERMATOMYOSITIS; NATURAL KILLER CELLS; PERIPHERAL BLOOD LYMPHOCYTE CELL SUBTYPES; T CELLS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DENDRITIC CELLS; DERMATOMYOSITIS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MALE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84879988508     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121031     Document Type: Article

References (44)

1. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995-1998: Results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003;49:300-5.
2. Rider LG, Miller FW. Idiopathic inflammatory muscle disease: Clinical aspects. Baillieres Best Pract Res Clin Rheumatol 2000;14:37-54.
3. Engel AG, Arahata K, Emslie-Smith A. Immune effector mechanisms in inflammatory myopathies. Res Publ Assoc Res Nerv Ment Dis 1990;68:141-57.
4. Engel AG, Arahata K. Mononuclear cells in myopathies: Quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986;17:704-21.
5. Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum 1982;25:126-39.
6. Li CK, Varsani H, Holton JL, Gao B, Woo P, Wedderburn LR. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol 2004;31:605-9.
7. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007;69:2008-19.
8. Lopez de Padilla CM, Vallejo AN, McNallan KT, Vehe R, Smith SA, Dietz AB, et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007;56:1658-68.
9. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986;314:329-34.
10. Tezak Z, Hoffman EP, Lutz JL, Fedczyna TO, Stephan D, Bremer EG. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: A novel model of pathogenesis. J Immunol 2002;168:4154-63.
11. Nagaraju K, Rider LG, Fan C, Chen YW, Mitsak M, Rawat R, et al. Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis 2006;3:2.
12. Liu YJ. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306.
13. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-78.
14. Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Elevated serum interferon-〈 activity in juvenile dermatomyositis: Associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum 2009;60:1815-24.
15. O'Gorman MR, Corrochano V, Roleck J, Donovan M, Pachman LM. Flow cytometric analysis of the lymphocyte subsets in peripheral blood of children with untreated active juvenile dermatomyositis. Clin Diagn Lab Immunol 1995;2:205-8.
16. Eisenstein DM, O'Gorman MR, Pachman LM. Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis. J Rheumatol 1997;24:1830-2.
17. Aleksza M, Szegedi A, Antal-Szalmás P, Irinyi B, Gergely L, Ponyi A, et al. Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis. Ann Rheum Dis 2005;64:1485-9.
18. Ishii W, Matsuda M, Shimojima Y, Itoh S, Sumida T, Ikeda S. Flow cytometric analysis of lymphocyte subpopulations and Th1/Th2 balance in patients with polymyositis and dermatomyositis. Intern Med 2008;47:1593-9.
19. Iannone F, Cauli A, Yanni G, Kingsley GH, Isenberg DA, Corrigall V, et al. T-lymphocyte immunophenotyping in polymyositis and dermatomyositis. Br J Rheumatol 1996;35:839-45.
20. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-40.
21. Tian Z, Gershwin ME, Zhang C. Regulatory NK cells in autoimmune disease. J Autoimmun 2012;39:206-15.
22. Gonzalez-Amaro R, Alcocer-Varela J, Alarcón-Segovia D. Natural killer cell activity in the systemic connective tissue diseases. J Rheumatol 1988;15:1223-8.
23. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986;136:4480-6.
24. Pachman LM, Fedczyna TO, Lechman TS, Lutz J. Juvenile dermatomyositis: The association of the TNF〈-308A allele and disease chronicity. Curr Rheumatol Rep 2001;3:379-86.
25. O'Gorman MR, Bianchi L, Zaas D, Corrochano V, Pachman LM. Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis. Clin Diagn Lab Immunol 2000;7:693-7.
26. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
27. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
28. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, et al Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004;50:1595-603.
29. Rider LG, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB, Zemel LS, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1997;40:1976-83.
30. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262-73.
31. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al, for the International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281-90.
32. Chiu YE, Co DO. Juvenile dermatomyositis: Immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. Pediatr Dermatol 2011;28:357-67.
33. Capelletti C, Baggi F, Zolezzi F, Biancolini D, Beretta O, Severa M, et al. Type 1 interferon and toll-like receptor expression characterizes inflammatory myopathies. Neurology 2011; 76:2079-88.
34. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, et al. Viral infection and toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004;34:796-805.
35. Greenberg SA, Pinkus GS, Amato AA, Pinkus JL. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007;35:17-23.
36. López de Padilla CM, Reed AM. Dendritic cells and the immunopathogenesis of idiopathic inflammatory myopathies. Curr Opin Rheum 2008;20:669-74.
37. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 2010;234:142-62.
38. Page G, Chevrel G, Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum 2004;50:199-208.
39. López de Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 2009;60:1160-72.
40. Ishida T, Matsumoto Y, Ohashi M, Sasaki R. Analysis of lymphocyte subpopulations in peripheral blood in adult and juvenile cases of dermatomyositis. J Dermatol 1993;20:30-4.
41. Miller FW, Love LA, Barbieri SA, Balow JE, Plotz PH. Lymphocyte activation markers in idiopathic myositis: Changes with disease activity and differences among clinical and autoantibody subgroups. Clin Exp Immunol 1990;81:373-9.
42. Jacobs R, Stoll M, Stratmann G, Leo R, Link H, Schmidt RE. CD16-CD56+ natural killer cells after bone marrow transplantation. Blood 1992;79:3239-44.
43. Voss SD, Robb RJ, Weil-Hillman G, Hank JA, Suqamura K, Tsudo M, et al. Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: P70 expression does not alone predict the level of intermediate affinity IL-2 binding. J Exp Med 1990;172:1101-14.
44. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, et al. Characterization of CD56-/CD16+ natural killer (NK) cells: A highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 2005;102:2886-91.